- Home
- ARTL
ARTL
Artelo Biosciences Inc.
as 12-18-2024 2:31pm EST
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | SOLANA BEACH |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 42.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.85 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $1.75 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Artelo Biosciences Inc. News
ARTL Breaking Stock News: Dive into ARTL Ticker-Specific Updates for Smart Investing
TipRanks
8 days ago
Artelo presents Phase 1 data with ART27.13 in cancer-related anorexia
GlobeNewswire
9 days ago
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
GlobeNewswire
a month ago
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
GlobeNewswire
a month ago
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
GlobeNewswire
a month ago
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
GlobeNewswire
2 months ago
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
GlobeNewswire
3 months ago
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compare ARTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARTL Artelo Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.